Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 11/20 | 0.52 |
| ▸ | MMP12 | P39900 | 6/20 | 0.52 |
| ▸ | MMP1 | P03956 | 5/20 | 0.50 |
| ▸ | MMP2 | P08253 | 5/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.50 |
| ▸ | MMP7 | P09237 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 5/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6577251 | 1.00 | MMP13 (0.52) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL6579833 | 0.98 | MMP13 (0.52) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL7486683 | 0.98 | MMP13 (0.52) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL6579654 | 0.98 | MMP13 (0.52) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL7430753 | 0.97 | MMP13 (0.51) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL6577310 | 0.97 | MMP13 (0.51) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL6577479 | 0.97 | MMP13 (0.51) | MMP13MMP12MMP1MMP2MMP3 | |
| SCHEMBL7430701 | 0.89 | MMP12 (0.65) | MMP13MMP12MMP2MMP3MMP9 | |
| SCHEMBL6579575 | 0.89 | MMP12 (0.65) | MMP13MMP12MMP2MMP3MMP9 | |
| SCHEMBL6579319 | 0.89 | MMP12 (0.65) | MMP13MMP12MMP2MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | claimed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | claimed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| EP-1100792-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006561-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | claimed |
| EP-1100792-B1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6492422-B2 | GELATINASE A, COLLAGENASE-3, AND STROMELYSIN-1 INHIBITOR AND USEFUL FOR THE TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AROTIC ANEURYSM, HEART FAILURE, RESTENOSIS, PERIODONTAL DISEASE OR AUTOIMMUNE | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | disclosed |
| US-6420408-B1 | MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, CARDIOVASCULAR DISORDERS, RESTENOSIS, PERIODONTAL DISEASE, AUTOIMMUNE OR INFLAMMATORY DISORDERS, ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, CEREBRAL AMYLOID ANGIOPATHY, | WARNER-LAMBERT COMPANY | 2002-07-16 | — | — | US | disclosed |
| EP-1100792-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006561-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169164-A1 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | MMP3, MMP12, MMP8 | MMP13 6/4885MMP12 2/4885MMP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.